provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content
HomeDrugsWegovy

Semaglutide for Weight Loss: How It Works and Compares to Other Weight-Loss Medications

Alyssa Billingsley, PharmDJoshua Murdock, PharmD, BCBBS
Updated on July 2, 2025

Key takeaways:

  • Semaglutide (marketed as Wegovy) is a once-weekly injectable weight-loss medication. It works best when used in combination with a nutritious diet and regular exercise.

  • During clinical trials, adults using semaglutide lost an average of almost 15% of their initial body weight. Adolescent clinical trials also showed an average weight loss of 15%.

  • There are many ways to save on Wegovy, the version of semaglutide approved for weight loss. If you’re eligible, a manufacturer savings card can help you access Wegovy for as little as $0.

Access savings on related medications

Woman prepping her stomach injection.
timnewman/E+ via Getty Images

In June 2021, the FDA approved semaglutide (Wegovy), a once-weekly injection for weight loss in adults. But semaglutide was making headlines even before its approval. That’s because people using it during clinical trials lost 15% to 18% of their starting body weight. This was more than other weight-loss medications on the market.

Since then, semaglutide has been approved for weight loss in adolescents ages 12 and older and heart protection in certain people with heart disease. And it’s being researched for a growing list of other potential uses, too.

So, is using semaglutide for weight loss right for you? While it may work better than some other weight-loss medications, there are other factors to consider. Let’s review what you should know about semaglutide.

What is semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It was originally approved in 2017 as Ozempic, a once-weekly injection for adults living with Type 2 diabetes. The FDA approved Rybelsus, a once-daily pill version of semaglutide, a few years later.

People using semaglutide for Type 2 diabetes also tend to lose weight as an additional benefit. Because of this, the manufacturer studied the medication specifically for weight loss, but at a higher dose. This led to the approval of Wegovy in 2021 — the first once-weekly GLP-1 receptor agonist for weight loss.

More recently, semaglutide (as Wegovy) has been approved for cardiovascular benefits in adults with a larger body size who have heart disease. If you have heart disease, Wegovy can help lower your risk of serious cardiovascular problems. It’s currently the only weight-loss medication approved for this use.

Good to know: There are compounded and research-grade versions of semaglutide on the market. These are not the same as the FDA-approved semaglutide products sold as Wegovy, Ozempic, or Rybelsus. The safety and effectiveness of unapproved versions of semaglutide haven’t been confirmed.

How does semaglutide work for weight loss?

Semaglutide mimics GLP-1, an incretin hormone that plays a role in appetite and digestion. It’s thought to work in a few different ways to help you lose weight. These include:

  • Slowing the movement of food out of your stomach (gastric emptying)

  • Targeting areas of the brain that help regulate appetite and fullness

  • Reducing cravings for certain foods, such as salty snacks or sweets

Certain semaglutide effects, such as slowed gastric emptying, may lessen over time. Other semaglutide effects, such as appetite reduction, only last as long as you’re using the medication.

01:57
Reviewed by Alexandra Schwarz, MD | August 7, 2023

Who should take semaglutide for weight loss?

Before starting semaglutide for weight loss, discuss the potential benefits and risk of treatment with your healthcare team. That’s because semaglutide isn’t right for everyone. It’s also a long-term commitment since rebound weight gain is possible if you stop using it.

For weight loss, semaglutide was studied in certain adults and adolescents who met established body mass index (BMI) criteria. As Wegovy, it’s currently approved for the following groups:

  • Adults and adolescents ages 12 and older who are considered to be obese

  • Adults who are considered to be overweight and have at least one weight-related health condition, such as high blood pressure or high cholesterol

Save up to 17% on wegovy with GoodRxDifferent pharmacies offer different prices for the same medication. GoodRx helps find the best price for you.
Save up to 17% on wegovy with GoodRxDifferent pharmacies offer different prices for the same medication. GoodRx helps find the best price for you.

Semaglutide is sometimes prescribed off-label for people who don’t meet the above criteria. This means the FDA hasn’t confirmed that semaglutide is safe and effective for these uses. Even so, your healthcare team may decide that semaglutide is appropriate for you.

What is the semaglutide dosage for weight loss?

Semaglutide is injected once a week, on the same day each week. It can be injected at any time of day, without regard to meals. 

You’ll typically start with a low semaglutide dose and work your way up every 4 weeks until reaching 2.4 mg once weekly — the target maintenance dose. But if you can’t tolerate the 2.4 mg dose, you may be instructed to inject 1.7 mg weekly as your maintenance dose. 

Promotion disclosure
Avg retail price
$1646.45(Save 19.87%)
GoodRx discount
$1319.23
How it works
drug-savings-illustration-1Use GoodRx to find medications, pharmacies, and discounts.
drug-savings-illustration-2GoodRx discounts can help you pay less for your prescription.
drug-savings-illustration-3Bring your free coupon or savings card to the pharmacy.

This semaglutide dosage schedule is meant to help manage potential side effects. If you’re unable to tolerate semaglutide, your prescriber may lower your dose or have you stop using it.

But what happens if you miss your semaglutide dose? Don’t panic — there are ways to get back on track. If your next scheduled dose is more than 2 days (48 hours) away, inject your missed dose and resume your usual schedule. But if your next dose is within 2 days, skip the dose you missed and start again on your regular injection day.

How to inject semaglutide

Wegovy, the semaglutide product approved for weight loss, is available as a single-use injection pen. Your dose is already pre-set for you and the needle is already attached to the pen. Each pen contains one dose, so you’ll throw it away after your injection. Here are some general steps to follow:

  • Choose your injection site. Inject your dose just under the skin (subcutaneously) of your abdomen, upper arm, or thigh. If you choose the upper arm, it’s best to have someone else give you the injection. Rotate injection sites each week to help limit injection site reactions.

  • Prepare the site. Clear the area with an alcohol swab and let it dry. Don’t blow on the area to make it dry faster.

  • Remove the pen cap. Do this right before you’re ready to inject. After removing the cap, you won’t see a needle since it’s hidden inside the needle cover.

  • Inject your dose. Push the pen firmly against your skin, which will trigger the injection. You should hear a “click” and the yellow bar should start moving, followed by a second click. Continue holding the pen here until the bar stops.

  • Dispose of the pen. Throw your used pen into a sharps container.

Keep in mind that Ozempic, another semaglutide injection, is sometimes prescribed off-label for weight loss. The Ozempic injection pen works differently compared to the Wegovy pen. You’ll also follow different instructions if you’ve been prescribed compounded semaglutide, which usually comes in a vial with syringes.

What do we know about semaglutide side effects?

Gastrointestinal side effects tend to happen most frequently with semaglutide for weight loss. They’re usually more pronounced when you first start semaglutide and after your dose is increased. Examples of common semaglutide side effects include:

GoodRx icon

While rare, semaglutide has been linked to potentially serious side effects. These include:

The FDA has also issued a boxed warning for semaglutide and its possible increased risk for thyroid C-cell tumors. There are no reports of humans developing these tumors from semaglutide, but it was reported in animal studies.

Can semaglutide interact with other medications?

Yes. Semaglutide can interact with diabetes medications, especially insulin and those that increase insulin release (such as sulfonylureas). These combinations can increase the risk of your blood sugar levels dropping too low (hypoglycemia).

Since semaglutide slows gastric emptying, it may potentially interfere with how your body absorbs oral medications. As mentioned above, this effect may only be a concern within the first several months of treatment. Your healthcare team can determine which interactions potentially affect you and how to manage them.

It’s also a good idea to avoid or limit alcohol while taking semaglutide. Alcohol may worsen certain side effects, sabotage weight-loss progress, and offset cardiovascular benefits.

How does semaglutide compare to other weight-loss medications?

The largest clinical trial studying semaglutide in adults showed an average weight loss of about 15% of initial body weight over 68 weeks (almost 16 months). Over the same length of time in another study, adolescents lost 15% of their initial body weight on average.

So, how does semaglutide stack up against other weight-loss medications?

Infographic comparing 8 weight loss medications side by side

Semaglutide vs. common weight-loss pills

There are several oral weight loss pills available. Oral weight-loss medications tend to be less expensive than the injectable options. But you may not lose as much weight.

Phentermine: Phentermine (Adipex-P) is a popular oral weight-loss medication that has been around since 1959. It’s approved for short-term use (up to 12 weeks), and it’s inexpensive. However, it’s possible to develop a tolerance to phentermine where it’s no longer working for you. Plus, it’s a controlled substance, meaning that it has a risk of dependency and misuse.

Qsymia: Phentermine is also available in combination with topiramate under the brand name Qsymia. Compared to phentermine alone, Qsymia is approved to be taken for a longer period of time. Study results have shown average weight loss ranging from about 5% (at lower doses) to around 10% (at higher doses). But unlike other weight-loss medications, you have to enroll in Qsymia’s mandatory risk management program if you’re able to get pregnant. This is required since Qysmia can harm a growing fetus.

Contrave: Contrave (bupropion / naltrexone) is another medication used for weight loss. One study showed that people taking Contrave in combination with diet and exercise lost an average of about 9% of their baseline body weight after 56 weeks. Contrave also has several drug interactions to consider.

Liraglutide vs. semaglutide

Liraglutide (Saxenda) was the first GLP-1 receptor agonist approved for weight loss. It’s a short-acting injection that needs to be administered once a day. In clinical studies, people lost an average of about 8% of their starting body weight after 56 weeks.

Semaglutide, by contrast, stays in the body longer and is injected once a week. It was the first once-weekly GLP-1 approved for weight loss and has shown greater weight loss results in clinical trials.

Both liraglutide and semaglutide are approved for use in adults and adolescents ages 12 and older. But only semaglutide is also approved to lower the risk of serious cardiovascular problems in certain people, with or without diabetes.

Tirzepatide vs. semaglutide

Tirzepatide (Zepbound) is a once-weekly injection approved for adults living with moderate-to-severe obstructive sleep apnea as well as for adult weight loss. It’s also sold as Mounjaro to treat adults living with Type 2 diabetes. Like semaglutide, tirzepatide mimics GLP-1. But it also mimics glucose-dependent insulinotropic polypeptide (GIP), which can have additional benefits.

During a trial comparing both medications for weight loss, people using tirzepatide lost more weight (20% of their starting weight) than those using semaglutide (14%). But unlike semaglutide, tirzepatide isn’t approved for cardiovascular benefits yet.

How to save on semaglutide

There are ways to save on semaglutide, which is available as brand-name Wegovy. 

  • Save with a manufacturer savings card. If you have commercial insurance, you may be eligible to pay as little as $0 for Wegovy using a savings card from the manufacturer. If you’re uninsured or paying cash, the price is as low as $499 per month.

  • Save with GoodRx. Save 14% off the average retail price of Wegovy at certain pharmacies with a free GoodRx coupon.

  • Save with direct pharmacy options. Get Wegovy delivered to your home for as low as $499 per month through NovoCare Pharmacy.

Frequently asked questions

How much do you lose on average with semaglutide?

In clinical trials, people using semaglutide for weight loss lost about 15% of their starting body weight at 68 weeks (almost 16 months). Individual results can vary based on your dose, lifestyle changes, and other factors.

How can you get a semaglutide prescription for weight loss?

A licensed healthcare professional must first decide if semaglutide is right for you based on your medical history, body weight, and health goals. You can get evaluated in person or through a telehealth visit, depending on your state’s rules. If approved, your prescriber can send your prescription to a pharmacy for pickup or delivery.

Are weight loss injections safe in the long-term?

Studies so far suggest that GLP-1 weight-loss injections like semaglutide are generally safe when used as directed. But because they’re still relatively new, researchers are still learning about potential long-term side effects and risks. Talk to your healthcare team about long-term safety and whether this type of treatment is right for you.

The bottom line

Semaglutide (Wegovy) is a once-weekly injection that can support weight loss when combined with positive lifestyle changes, such as routine exercise and a nutritious diet. It’s also FDA approved to lower the risk of serious cardiovascular problems in certain people, making it a unique option among weight-loss medications.

During clinical trials, people using semaglutide on average lost about 15% of their starting body weight. While it can work well for many people, semaglutide isn’t right for everyone. It also has side effects, interactions, and ongoing costs to consider. Talk to your healthcare team to see if semaglutide is a good fit for your treatment plan.

why trust our exports reliability shield

Why trust our experts?

Alyssa Billingsley, PharmD
Alyssa Billingsley, PharmD, is the director of pharmacy content for GoodRx. She has over a decade of experience as a pharmacist and has worked in clinical, academic, and administrative roles.
Joshua Murdock, PharmD, BCBBS
Joshua Murdock, PharmD, BCBBS, is a licensed pharmacist in Arizona, Colorado, and Rhode Island. He has worked in the pharmacy industry for more than 10 years and currently serves as a pharmacy editor for GoodRx.

References

Aronne, L. J., et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. The New England Journal of Medicine

Center for Connected Health Policy. (n.d.). Online prescribing.

View All References (14)

GlobeNewswire. (2020). Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management.

GlobeNewswire. (2021). Wegovy (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US.

Lonneman, D. J., Jr., et al. (2013). Phentermine/topiramate extended-release capsules (Qsymia) for weight loss. P & T.

NovoCare. (2025). NovoCare Pharmacy

Novo Nordisk. (2017). Ozempic (semaglutide) approved in the US.

Novo Nordisk. (2022). FDA approves once-weekly Wegovy injection for the treatment of obesity in teens aged 12 years and older.

Novo Nordisk. (2023). Novo Nordisk announces FDA approval of label update for Rybelsus (semaglutide) allowing use as a first-line option for adults with type 2 diabetes

Novo Nordisk. (2024). Wegovy semaglutide injection 2.4mg [package insert]

Pi-Sunyer, X., et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. The New England Journal of Medicine.

Qsymia. (2024). Risk evaluation and mitigation strategy (REMS).

U.S. Food and Drug Administration. (2024). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight

Wadden, T. A., et al. (2012). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity

Weghuber, D., et al. (2022). Once-weekly semaglutide in adolescents with obesity. The New England Journal of Medicine.

Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine.

GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.

Was this page helpful?

Your Guide to Sustainable Weight Loss

Our 6-day newsletter series breaks down the latest medications and how you can achieve sustainable weight loss.

By providing your email, you consent to receive marketing communications from GoodRx, which may include content and/or data related to men’s health, women's health, reproductive care, or sexual health. You agree to the GoodRx Terms of Use and acknowledge the Privacy Policy. You can unsubscribe at any time.

Related Articles

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.